Abstract |
Methylglyoxal-bis(guanylhydrazone) ( MGBG; NSC 32946), a competitive inhibitor of S-adenosyl-L-methionine decarboxylase (EC 4.1.1.50), currently being reevaluated for its clinical antileukemic activity. MGBG labeled with 14C in the guanylhydrazone moiety was administered i.v. (150 microCi; specific activity, 1.9 microCi/mumol; 20 mg total) to six patients with leukemia. All patients in the study had normal renal and hepatic function. [14C] MGBG underwent no in vivo metabolism; it disappeared from the plasma with an average terminal t 1/2 of 4.1 hr. The 72-hr cumulative urinary excretion was only 14.5 +/- 2.2% (S.E.M.) of the total radioactive dose. The apparent volume of distribution was 661 ml/kg and the total clearance rate was 21.2 ml/kg/min. The low urinary excretion rate and the relatively rapid plasma clearance suggest that MGBG may be sequestered in the body. Therefore, if MGBG is administered by a frequent treatment schedule, the prolonged biological half-life in humans may significantly contribute to its clinical toxicity.
|
Authors | M G Rosenblum, M J Keating, B S Yap, T L Loo |
Journal | Cancer research
(Cancer Res)
Vol. 41
Issue 5
Pg. 1748-50
(May 1981)
ISSN: 0008-5472 [Print] United States |
PMID | 7214342
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Drug Evaluation
- Guanidines
(metabolism)
- Humans
- Kinetics
- Leukemia
(drug therapy)
- Metabolic Clearance Rate
- Mitoguazone
(metabolism, therapeutic use, urine)
|